75 results
PRE 14C
BTAX
Biostax Corp.
16 Dec 22
Preliminary information
4:31pm
)
Payment of Filing Fee (Check all boxes that apply):
☒ No fee required.
☐ Fee paid previously with preliminary materials.
☐ Fee computed on table … custodians for their reasonable expenses for forwarding information materials to the beneficial owners of our common stock. We do not anticipate
8-K
EX-10.2
BTAX
Biostax Corp.
9 Nov 22
Entry into a Material Definitive Agreement
5:00pm
that upon termination of this Agreement, it will promptly deliver to the Company all written and other materials in its possession or control which
8-K
EX-10.1
BTAX
Biostax Corp.
9 Nov 22
Entry into a Material Definitive Agreement
5:00pm
, it will promptly deliver to the Company all written and other materials in its possession or control which contain any of the trade secrets
8-K
EX-17.1
60bcfe 3q3lkh5
9 Nov 22
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
9v0514okf2 qm
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
D
y9qgtve1q7tcy2 bu
31 Aug 22
$5M in debt
2:58pm
8-K
EX-10.1
lzz8bamwkubwh
22 Jul 22
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
3:44pm
8-K
EX-99.1
30q4n19pd5r3s2r3nag
22 Oct 20
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs
4:33pm
8-K
EX-10.1
d34uno jmkd
27 Jul 20
Departure of Directors or Certain Officers
3:07pm
8-K
fk0rwq 0xm9
14 May 20
Other Events
10:08am
DEFR14A
fwssy2kteasd3kxqdxw
21 Oct 19
Revised proxy
2:40pm